In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at to determine how to proceed.

GeneDx logo
Photo of Melanie Duquette

Melanie Duquette

Chief Growth Officer

Melanie Duquette is Chief Growth Officer of GeneDx, driving commercial excellence as she leads both the company’s commercial growth strategy and the sales, market access, clinician marketing, and client services teams. 

Melanie’s career has been guided by her passion for increasing access to genetic testing globally, and she spent the past two decades defining and executing profitable commercial growth strategies to expand utilization of genetic testing. 

Prior to joining GeneDx, Melanie was the Vice President of U.S. Sales at Invitae Corporation (NVTA), leading a sales and business development organization of more than 200 people and executing a commercial strategy that shifted the team toward profitable growth. Prior to that, she led the company’s entry and rapid expansion into more than 100 international markets, driving greater than 50% year-over-year growth for five consecutive years.   

Before joining Invitae, Melanie served as Director of International Sales at DNA Genotek (now Orasure Technologies), a medical device company focused on genetic testing and research.  Melanie joined DNA Genotek in its early commercialization phase and was instrumental in launching and growing the utilization of their flagship product, Oragene, which is now the gold standard for remote sample collection in the genetic testing space.   

Melanie holds a bachelor’s degree in Biopharmaceutical Science with a concentration in Genomics from the University of Ottawa.